Tagged with R

biotech Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently ranked eighth. “Boryung is the only domestic company that has developed a drug from start to finish, including outlicensing. Of…

clinical trials The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303 in 2012, with 367 clinical trials performed by local companies. In the same year, Seoul was ranked the number one…

biotech Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their second generation botulinum toxin product that will be commercialized globally (outside of Japan and Korea) by Botox manufacturer Allergan. What…

CRM Starting a new business is no easy task. The general manager of Alliance SFA shares his experience, how he decided to focus on second-tier and niche players to offer tailor-made CRM solutions to optimize sales force performance and innovative channels to approach an increasingly informed patient. What was the vision…

generics Founded back in 1956, Laboratorios Keton is a small 100 percent Mexican company committed to provide high-quality contract manufacturing services to local as well as international drug makers. With more than 50 years of experience in the pharmaceutical industry, the founder discusses the company’s most important milestones, achieved under the…

local The general manager explains how vision behind the setting up of Grupo Rasch was to represent companies, primarily European and high-tech ones, in the manufacturing of drugs reveals and how his relationship with his business partner, Federico Scharrer, is the bedrock of the group’s success Grupo Rasch recently celebrated its…

Janssen Janssen’s MD in Turkey discusses how true innovation is still recognized in Turkey, and how products that meet unmet medical needs are given early access to the country and reimbursement. Based on current discussions, what is your expectation for how pricing reforms will transpire when they begin?  The government is…

consulting IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such as the growing specialty drugs segment and shift towards the hospital sales channel. What changes have you seen in the…

Otsuka The managing director of Otsuka’s 50-50 joint venture with Turkish giant Abdi Ibrahim, Abdi Ibrahim Otsuka, discusses the mutual advantage the companies can offer each other, and branding Abdi Ibrahim Otsuka as an innovative player on the Turkish arena. What were the initial aspirations in establishing the joint venture between…

government Turkey’s Minister of Health discusses the major achievements of his party in the area of healthcare since 2003, and the key priorities for the country’s healthcare system moving forward. During AKP’s (Justice and Development Party) incumbency, what were the main policies in health, and what are your priorities for future…

World Medicine The founder and chairman of the rapidly expanding World Medicine group of companies discusses his firm’s international expansion strategy, how he came to the decision to invest in production and R&D facilities in Turkey, and the strong support World Medicine has from the Turkish government. How did you originally come…

association The secretary general of the innovators’ association gives an overview of the current structural challenges facing the pharmaceutical industry in Turkey, and discusses the changes that need to be introduced for the vast potential of the Turkish pharmaceutical industry to be unlocked.   Could you give our readers a brief…